Celularity Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Celularity Inc. on December 19, 2024. The company is incorporated in Delaware and its Class A Common Stock trades on The Nasdaq Stock Market under the symbol CELU.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Director
- Robert J. Hariri, M.D., Ph.D. was elected as the Class III Director to serve until the 2027 Annual Meeting.
- Votes For: 10,250,294
- Votes Withheld: 53,960
- Broker Non-Votes: 3,285,202
- Proposal 2: Ratification of Auditors
- Stockholders ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Votes For: 13,561,068
- Votes Against: 24,211
- Abstentions: 4,177
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It strictly details the certified results of the stockholder vote.
Investor Verification Checklist
- Verify the definitive proxy statement (Schedule 14A) filed on November 19, 2024, for detailed background on the director nominee and auditor appointment.
- Confirm the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.